Serotonin receptor 2B signaling with interstitial cell activation and leaflet remodeling in degenerative mitral regurgitation.

AIMS Mitral valve interstitial cells (MVIC) play an important role in the pathogenesis of degenerative mitral regurgitation (MR) due to mitral valve prolapse (MVP). Numerous clinical studies have observed serotonin (5HT) dysregulation in cardiac valvulopathies; however, the impact of 5HT-mediated signaling on MVIC activation and leaflet remodeling in MVP have been investigated to a limited extent. Here we test the hypothesis that 5HT receptors (5HTRs) signaling contributes to MVP pathophysiology. METHODS AND RESULTS Diseased human MV leaflets were obtained during cardiac surgery for MVP; normal MV leaflets were obtained from heart transplants. MV RNA was used for microarray analysis of MVP patients versus control, highlighting genes that indicate the involvement of 5HTR pathways and extracellular matrix remodeling in MVP. Human MV leaflets were also studied in vitro and ex vivo with biomechanical testing to assess remodeling in the presence of a 5HTR2B antagonist (LY272015). MVP leaflets from Cavalier King Charles Spaniels were used as a naturally acquired in vivo model of MVP. These canine MVP leaflets (N=5/group) showed 5HTR2B upregulation. This study also utilized CB57.1ML/6 mice in order to determine the effect of Angiotensin II infusion on MV remodeling. Histological analysis showed that MV thickening due to chronic Angiotensin II remodeling is mitigated by a 5HTR2B antagonist (LY272015) but not by 5HTR2A inhibitors. CONCLUSION In humans, MVP is associated with an upregulation in 5HTR2B expression and increased 5HT receptor signaling in the leaflets. Antagonism of 5HTR2B mitigates MVIC activation in vitro and MV remodeling in vivo. These observations support the view that 5HTR signaling is involved not only in previously reported 5HT-related valvulopathies, but it is also involved in the pathological remodeling of MVP.

[1]  J. Bavaria,et al.  Oxidative stress modulates vascular smooth muscle cell phenotype via CTGF in thoracic aortic aneurysm. , 2013, Cardiovascular research.

[2]  Robert J Levy,et al.  Serotonin transporter mechanisms and cardiac disease. , 2005, Circulation.

[3]  J. Bavaria,et al.  Circulating Soluble Receptor for Advanced Glycation End Product Identifies Patients With Bicuspid Aortic Valve and Associated Aortopathies , 2014, Arteriosclerosis, thrombosis, and vascular biology.

[4]  R. Sainger,et al.  Osteopontin controls endothelial cell migration in vitro and in excised human valvular tissue from patients with calcific aortic stenosis and controls , 2011, Journal of cellular physiology.

[5]  Mansher Singh,et al.  Modulation of Transforming Growth Factor-&bgr; Signaling and Extracellular Matrix Production in Myxomatous Mitral Valves by Angiotensin II Receptor Blockers , 2012, Circulation.

[6]  A. K. Stunes,et al.  Long-term serotonin effects in the rat are prevented by terguride , 2007, Regulatory Peptides.

[7]  Jie-yu Ye,et al.  Serotonin Enhances Megakaryopoiesis and Proplatelet Formation via p‐Erk1/2 and F‐Actin Reorganization , 2014, Stem cells.

[8]  F. Guilak,et al.  Correlation between heart valve interstitial cell stiffness and transvalvular pressure: implications for collagen biosynthesis. , 2006, American journal of physiology. Heart and circulatory physiology.

[9]  R. Levine,et al.  Mitral valve prolapse and atrial septal aneurysm: an evaluation in the Framingham Heart Study. , 2002, The American journal of cardiology.

[10]  L. Daws,et al.  Ontogeny and regulation of the serotonin transporter: providing insights into human disorders. , 2011, Pharmacology & therapeutics.

[11]  Hai Lin,et al.  Differences in tissue-remodeling potential of aortic and pulmonary heart valve interstitial cells. , 2007, Tissue engineering.

[12]  Bryan L Roth,et al.  Molecular Determinants for the Interaction of the Valvulopathic Anorexigen Norfenfluramine with the 5-HT2B Receptor , 2005, Molecular Pharmacology.

[13]  A. Schapira,et al.  Drug-induced fibrotic valvular heart disease , 2009, The Lancet.

[14]  T. Guy,et al.  Mitral valve prolapse. , 2012, Annual review of medicine.

[15]  Christopher A. Carruthers,et al.  Quantification and simulation of layer-specific mitral valve interstitial cells deformation under physiological loading. , 2015, Journal of theoretical biology.

[16]  R. Levy,et al.  Fenfluramine disrupts the mitral valve interstitial cell response to serotonin. , 2009, The American journal of pathology.

[17]  D. Argyle,et al.  Gene network and canonical pathway analysis in canine myxomatous mitral valve disease: a microarray study. , 2015, Veterinary journal.

[18]  R. Levy,et al.  Serum serotonin concentrations in dogs with degenerative mitral valve disease. , 2009, Journal of veterinary internal medicine.

[19]  R. M. Lightfoot,et al.  5-Hydroxytryptamine (5HT) Receptors in the Heart Valves of Cynomolgus Monkeys and Sprague-Dawley Rats , 2005, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[20]  R. Rothman.  Anorexogen-Related Cardiac Valvulopathy , 2002, Annals of Internal Medicine.

[21]  Daniel Hoyer,et al.  Molecular, pharmacological and functional diversity of 5-HT receptors , 2002, Pharmacology Biochemistry and Behavior.

[22]  M. Daniels,et al.  Architectural Trends in the Human Normal and Bicuspid Aortic Valve Leaflet and Its Relevance to Valve Disease , 2014, Annals of Biomedical Engineering.

[23]  J. Bavaria,et al.  Antioxidant Enzymes Reduce DNA Damage and Early Activation of Valvular Interstitial Cells in Aortic Valve Sclerosis , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[24]  A. Yoganathan,et al.  In-vivo dynamic deformation of the mitral valve anterior leaflet. , 2006, The Annals of thoracic surgery.

[25]  K. J. Grande-Allen,et al.  Calcific Aortic Valve Disease : Not Simply a Degenerative Process A Review and Agenda for Research from the National Heart and Lung and Blood Institute Aortic Stenosis Working Group , 2012 .

[26]  S. Chittur,et al.  Genomic expression patterns of mitral valve tissues from dogs with degenerative mitral valve disease. , 2006, American journal of veterinary research.

[27]  Marie-Chloé Boulanger,et al.  Molecular biology of calcific aortic valve disease: towards new pharmacological therapies , 2014, Expert review of cardiovascular therapy.

[28]  R. Levy,et al.  Serotonin mechanisms in heart valve disease II: the 5-HT2 receptor and its signaling pathway in aortic valve interstitial cells. , 2002, The American journal of pathology.

[29]  Asha A. Nair,et al.  Nonbiased Molecular Screening Identifies Novel Molecular Regulators of Fibrogenic and Proliferative Signaling in Myxomatous Mitral Valve Disease , 2015, Circulation. Cardiovascular genetics.

[30]  R. Hinton,et al.  Heart valve structure and function in development and disease. , 2011, Annual review of physiology.

[31]  P. Pellikka,et al.  Carcinoid heart disease. , 2007, Progress in cardiovascular diseases.

[32]  E. Orton,et al.  Autocrine serotonin and transforming growth factor beta 1 signaling mediates spontaneous myxomatous mitral valve disease. , 2009, The Journal of heart valve disease.

[33]  C. Elangbam,et al.  5-hydroxytryptamine (5HT)-induced valvulopathy: compositional valvular alterations are associated with 5HT2B receptor and 5HT transporter transcript changes in Sprague-Dawley rats. , 2008, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.

[34]  R. Levy,et al.  Serotonin mechanisms in heart valve disease I: serotonin-induced up-regulation of transforming growth factor-beta1 via G-protein signal transduction in aortic valve interstitial cells. , 2002, The American journal of pathology.

[35]  J. Bavaria,et al.  Analysis of osteopontin levels for the identification of asymptomatic patients with calcific aortic valve disease. , 2012, The Annals of thoracic surgery.

[36]  R. Rothman,et al.  Neural and cardiac toxicities associated with 3,4-methylenedioxymethamphetamine (MDMA). , 2009, International review of neurobiology.

[37]  Thoralf M Sundt,et al.  2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.

[38]  J. Bavaria,et al.  Osteopontin–CD44v6 Interaction Mediates Calcium Deposition via Phospho-Akt in Valve Interstitial Cells From Patients With Noncalcified Aortic Valve Sclerosis , 2014, Arteriosclerosis, thrombosis, and vascular biology.

[39]  Thoralf M Sundt,et al.  2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Journal of the American College of Cardiology.

[40]  M. Yacoub,et al.  Cellular Mechanisms in Mitral Valve Disease , 2011, Journal of cardiovascular translational research.

[41]  B. Roth,et al.  Evidence for Possible Involvement of 5-HT2B Receptors in the Cardiac Valvulopathy Associated With Fenfluramine and Other Serotonergic Medications , 2000, Circulation.

[42]  J. Bavaria,et al.  Human myxomatous mitral valve prolapse: Role of bone morphogenetic protein 4 in valvular interstitial cell activation , 2012, Journal of cellular physiology.

[43]  R. Levy,et al.  Insights into serotonin signaling mechanisms associated with canine degenerative mitral valve disease. , 2010, Journal of veterinary internal medicine.

[44]  C. Huttenhower,et al.  Passing Messages between Biological Networks to Refine Predicted Interactions , 2013, PloS one.

[45]  M. Hamon,et al.  Deficiency of the 5-Hydroxytryptamine Transporter Gene Leads to Cardiac Fibrosis and Valvulopathy in Mice , 2005, Circulation.

[46]  R. Fossmark,et al.  Long-Term Serotonin Administration Induces Heart Valve Disease in Rats , 2005, Circulation.

[47]  J. Bavaria,et al.  Noggin attenuates the osteogenic activation of human valve interstitial cells in aortic valve sclerosis. , 2013, Cardiovascular research.